Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma

Jonathon B. Cohen, Brad S. Kahl

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Patients with early stage follicular lymphoma frequently have prolonged overall survival and 40% may remain progression-free 20 years after receiving radiation therapy alone. Thus, such an approach is often considered in this population. Patients with advanced-stage disease but low tumor burden do not achieve a survival benefit by initiation treatment but early therapy with rituximab can improve quality of life and prolong time until need for further treatment and/or chemotherapy. Patients with advanced-stage follicular lymphoma who have low tumor burden should be managed in a personalized fashion taking into account individual feeling regarding treatment, toxicity, and long-term goals.

Original languageEnglish
Pages (from-to)663-672
Number of pages10
JournalHematology/Oncology Clinics of North America
Issue number4
StatePublished - Aug 2020


  • Early stage
  • Follicular lymphoma
  • Low tumor burden
  • Non-Hodgkin lymphoma
  • Rituximab
  • Watchful waiting


Dive into the research topics of 'Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma'. Together they form a unique fingerprint.

Cite this